allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
Cell therapyexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1995 (NCT00002663)
Timeline
Indications
Mechanism of action
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
- allogeneic epstein-barr virus-specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01430390 | Phase 1 | Sep 1, 2011 | Cornell University |
| NCT00006100 | Phase 1 | Apr 1, 2000 | National Cancer Institute (NCI), Pennsylvania State University |
| NCT00005606 | Phase 2 | Feb 1, 2000 | National Cancer Institute (NCI), Northwestern University |
| NCT00002956 | Phase 1 | Nov 1, 1996 | University of Alabama, Birmingham |
| NCT00002663 | Phase 1/Phase 2 (Phase 2) | Mar 1, 1995 | Atara Biotherapeutics, Cornell University, National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1995 |
| Cornell University | Academic/Hospital | 2 | 1 | 2 | 1995 |
| Atara Biotherapeutics | For profit | 1 | 1 | 1 | 1995 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 1996 |
6 organizations
Page 1 / 1